Prednisolone may modulate inflammation in rheumatoid arthritis

Prednisolone may modulate inflammation and autoimmunity-associated pathogenetic mechanisms in early stage rheumatoid arthritis (RA).

A randomised a study of 225 patients over two years found the frequency of prednisolone-taking patients with radiographic progression was 26% compared with 39% for patients who did not take prednisolone.

The presence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide 2 (anti-CCP) generally predicted radiographic progression for RA patients who took disease